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ABSTRACT 
 
Access to antiretroviral therapy has been gradually increasing in resource limited 
settings, Zimbabwe included. Despite the increasing access to antiretroviral therapy 
quite a number of patients are still delaying to seek antiretroviral therapy. The 
purpose of the study was to examine factors associated with delay in seeking 
antiretroviral therapy.  
 
A survey was conducted at Parirenyatwa Hospital Opportunistic 
Infections/Antiretroviral Therapy Clinic from September and November 2012. A total 
of 80 participants starting antiretroviral therapy who met the criteria were included in 
the study. The inclusion criteria included patients 18 years above but less than 65 
years, no prior history of antiretroviral therapy and eligibility for antiretroviral therapy 
based on CD4 count or World Health Organisation clinical staging. An interviewer 
administered questionnaire containing demographic, socio-economic and health-
facility factors were used to collect data. Four weeks was used as a cut off point for 
delay in seeking antiretroviral therapy.  
  
The majority of participants (60%) delayed seeking antiretroviral therapy and the 
factors which were associated with delay in seeking antiretroviral therapy included 
female gender; lack of a partner; low level of education; low socio-economic status; 
treatment of opportunistic infections; extra laboratory tests on top of the CD4 count 
tests; not being on Cotrimoxazole Prophylaxis; not being referred for antiretroviral 
therapy by the testing site; stigma and discrimination. However disclosure was not 
associated with early seeking of antiretroviral therapy. Health system factors such as 
attitude of health care workers, shortage of staff and long waiting times were also 
identified as bottlenecks to patients seeking antiretroviral therapy early. 
 
Efforts to increase early starting of antiretroviral therapy should focus on addressing 
the referral system from testing sites to antiretroviral therapy initiating sites, 
improving efficiency of antiretroviral initiating sites, increasing point of care HIV & 
AIDS diagnostics tools and addressing patient‟s concerns such as stigma & 
discrimination. 
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OPSOMMING 
 
Toegang tot antiretrovirale terapie Geleidelik is steeds in hulpbron beperkte 
omgewing, Zimbabwe ingesluit. Ten spyte van die toenemende toegang tot 
antiretrovirale terapie 'n hele aantal van die pasiënte is nog steeds vertraag 
antiretrovirale terapie te soek. Die doel van die studie was om faktore te ondersoek 
wat verband hou met vertraging in die soek van antiretrovirale terapie. 
 
'n Opname is by Parirenyatwa-hospitaal opportunistiese infeksies / antiretrovirale 
terapie Clinic van September en November 2012. 'N totaal van 80 deelnemers begin 
antiretrovirale terapie wat met die kriteria wat in die studie ingesluit is. Die insluiting 
kriterium was pasiënte ouer as 18 jaar maar minder as 65 jaar, geen geskiedenis 
voor antiretrovirale terapie en in aanmerking kom vir antiretrovirale terapie gebaseer 
op CD4-telling of Kliniese stadiëring Wêreld Gesondheid Organisasie. Was 'n 
onderhoudvoerder vraelys met demografiese, sosio-ekonomiese faktore en 
gesondheid-fasiliteit wat gebruik word om data in te samel. 4 weke is gebruik as die 
afsny punt vir die vertraging in die soeke na antiretrovirale terapie. 
 
Die meerderheid van die deelnemers (60%) antiretrovirale terapie en die faktore wat 
verband hou met die vertraging in die soek na antiretrovirale terapie is vertraag te 
soek vroulike geslag, gebrek van 'n vennoot, lae vlak van onderwys, 'n lae sosio-
ekonomiese status, behandeling van opportunistiese infeksies; Ekstra 
laboratoriumtoetse op die top van die CD4-telling toetse nie op Cotrimoxazole 
Profilakse, nie vir antiretrovirale terapie verwys deur die toets site, stigma en 
diskriminasie. Egter openbaarmaking wat nie verband hou met die vroeë soek van 
antiretrovirale terapie. Gesondheid stelsel faktore soos houding van 
gesondheidsorgwerkers, tekort aan personeel en lang wagtye, is ook geïdentifiseer 
as knelpunte aan pasiënte op soek na vroeë antiretrovirale terapie 
 
Pogings om te vroeg begin van antiretrovirale terapie Verhoog Indien Fokus op die 
verwysingstelsel van die toets sites tot antiretrovirale terapie Inisiëring sites, 
verbetering van doeltreffendheid van antiretrovirale Inisiëring sites, Verhoog Punt 
Stellenbosch University  http://scholar.sun.ac.za
 
 
iv 
 
van Care MIV & VIGS diagnose tools en aanspreek van die pasiënt se Kommer 
Soos stigma en diskriminasie. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
v 
 
ACKNOWLEDGEMENTS 
 
I am very grateful for the dedication, patience and professional guidance of my 
supervisor Greg Munro during my research project. His wisdom and encouragement 
provided me with the much needed motivation to undertake such a demanding and 
exhausting endeavour.   
My sincere gratitude and appreciation to the Clinical Director, Supervising Consultant 
and Sister in Charge of Parirenyatwa OI/ART clinic for who kindly gave me the 
permission to conduct the research at the clinic. Many thanks go to the Sister in 
Charge, Sister Zvorwadza who assisted in introducing the research to potential 
participants and distribution of research documents. I also like to thank other staff 
members at the clinic who helped during the research. 
To Stellenbosch University, Africa Centre for HIV & AIDS Management, I will forever 
remain grateful for the support during the research project.  
To God Almighty, I thank you for the guidance throughout the process 
Finally, I am deeply indebted to the participants themselves who set aside their 
other, often more important duties and responsibilities to take part in this research.   
 
 
  
Stellenbosch University  http://scholar.sun.ac.za
 
 
vi 
 
ABBREVIATIONS 
 
AIDS   Acquired Immunodeficiency Syndrome 
ART    Antiretroviral Therapy 
HAART  Highly Active Antiretroviral Therapy 
HIV    Human Immunodeficiency Virus 
IRIS   Immune Reconstitution Inflammatory Syndrome 
JREC Joint Ethics Research Committee at Parirenyatwa 
Hospital and College of Health Sciences 
MOHCW  Ministry of Health & Child Welfare 
NAC   National AIDS Council 
OI   Opportunistic Infection(s) 
OIC    Opportunistic Infections Clinic 
PITC   Provider Initiated Testing & Counseling 
REC   Research Ethics Committee  
SU   Stellenbosch University 
UNAIDS  United Nations Joint Programme on AIDS 
VCT   Voluntary Counseling & Testing 
WHO   World Health Organisation 
  
Stellenbosch University  http://scholar.sun.ac.za
 
 
vii 
 
TABLE OF CONTENTS 
 
Declaration           i 
Opsomming / Abstract         ii 
Acknowledgements          iv 
Abbreviations           v 
Table of Contents          vi 
List of Figures & Tables         vii 
 
Chapter 1 
1.1 Background           1 
1.2 Research Problem          3 
1.3 Research Question          4 
1.4 Research Justification          4 
1.5 Aim and Objectives          5 
 
Chapter 2 - Literature Review         6 
 
Chapter 3 - Methodology 
3.1 Study Design & Population         9 
3.2 Sampling            9  
3.3 Data Collection           9 
3.4 Data Handling & Analysis        10 
3.5 Permission & Ethical Considerations       10 
 
Chapter 4 - Data Presentation & Analysis 
4.1 Results           11 
4.2 Discussion          24 
 
Chapter 5 
5.1 Conclusion          28 
5.2 Recommendations         29 
 
References           30 
 
Appendices 
Appendix 1 – Questionnaire        33 
Appendix 2 – Consent Form (English)       37 
Appendix 3 – Consent Form (Shona)       41 
Appendix 4 – Ethical Approval from SU REC      45 
Appendix 5 – Ethical Approval from JREC      46 
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
viii 
 
List of Figures & Tables 
 
Figures 
Figure 1: Days between Date of HIV Test and Date Started on Antiretroviral 
Therapy           11 
Figure 2: Cumulative Frequency of Patients Started on HAART after a Specific 
Period            12 
Figure 3: Participants that Delayed HAART with Sex     13 
Figure 4: Marital Status and Delayed HAART      13 
Figure 5: Employment Status versus Starting HAART Early or Delayed  14 
Figure 6: Level of Education and Delayed HAART     14 
Figure 7: Place of HIV Test        15 
Figure 8: Referral Letter and HAART Initiation      16 
Figure 9: Scatter Plot on Duration of Counseling Sessions for the 80 participants 17 
Figure 10: Place of CD4 Testing        18 
Figure 11: Extra Test(s) and Initiation of HAART     18 
Figure 12: Reasons for Not Being Started on HAART on the Booked Date  19 
Figure 13: Sexual Partner and HAART Initiation     20 
Figure 14: Stigma & Discrimination and HAART Initiation    21 
Figure 15: Residential Area and Delayed HAART Initiation    22 
Figure 16: Mode of Transport and HAART Initiation     22 
Figure 17: Quality of Service at Parirenyatwa OI/ART Clinic According to  
Participants           23 
 
Tables  
Table 1: Referral for HAART and Delayed HAART     16 
Table 2: Partner Antiretroviral Therapy Status and Initiation of HAART  20 
 
Stellenbosch University  http://scholar.sun.ac.za
 1 
 
CHAPTER 1 
 
1.1 BACKGROUND 
According to the World Health Organization Progress Report (WHO Progress 
Report, 2011), at the end of 2010 about 34 million people were infected with the HIV 
virus globally with more than 68 % of them living in Sub-Saharan Africa. Globally the 
number of new infections continues to decline though there are regional variations.  
Southern Africa is the region mostly affected by HIV worldwide with prevalence 
peaking between 10 and 40%. Zimbabwe is one of the four countries in the region 
(after Swaziland, Botswana and Lesotho) most severely hit by the epidemic (Sub – 
Saharan HIV and AIDS Statistics, 2009). However, Zimbabwe is the only country in 
the region which had a substantial decrease in HIV prevalence at national level. The 
decline from 29.6% in 2002 to current rate of 14.2% has been due to a number of 
factors which include mortality and reduction of new infections. The country has an 
estimated population of 12.1 million (Central Statistical Office, 2008) and by the end 
of 2009 it was estimated that 1.1 million people were living with the virus (Ministry of 
Health and Child Welfare, National HIV & AIDS Estimates 2009, (MOHCW, 2009)). 
The age group most affected (15-49) constitutes the most productive sector of 
society. The prevalence among this age group has dropped from 15.07 % in 2008 to 
14.26% in 2009  but this still remains unacceptably high (MOHCW, 2009). According 
to the National AIDS Council 2011, 3rd Quarter Report (NAC, 2011) the total number 
of clients (both adults and children) in need of ART in Zimbabwe stood at 593 000 in 
accordance with the WHO 2010 Guidelines that utilize a CD4 count of 350cells/mm3. 
About 382 000 adults and 37 000 children were on antiretroviral therapy by the end 
of the third quarter in 2011 (NAC, 2011).  
 
As part of the 3 by 5 initiative, in 2003, the Ministry of Health and Child Welfare set 
up five pilot clinics with the help of various partners. These clinics were meant to 
provide holistic care for the management of HIV/AIDS and to pave the way for the 
introduction of antiretroviral drugs in the public sector. The sites chosen for the five 
pilot clinics were Harare and Mpilo Central Hospitals, Triangle Hospital (a private 
hospital run by Triangle Sugar Estates), Khami Road clinic (a city council-run 
establishment in Bulawayo) and Howard Mission Hospital. These sites were chosen 
mainly because of the infrastructure that was already in place and some sites 
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already had Cotrimoxazole prophylaxis programs on site. Nationwide training of 
health care workers on the management of opportunistic infections and antiretroviral 
therapy was initiated in order to facilitate rolling out of the antiretroviral therapy (ART) 
program in Zimbabwe. National HIV & AIDS Treatment Guidelines were introduced 
together with the national first line and second line antiretroviral regimens. These 
guidelines have been regularly updated to be in line with current WHO guidelines. 
Operating protocols for the clinics were introduced in order to ensure standardization 
in the management of opportunistic infections and ART.   Antiretroviral therapy roll 
out in the public sector started in 2004 at the mentioned 5 pilot sites.  
 
Parirenyatwa Hospital is the largest referral hospital in Zimbabwe and it has several 
departments which include surgical, medical, pediatrics, outpatients and the 
Opportunistic Infections/Antiretroviral Therapy (OI/ART) clinic where HIV & AIDS 
patients are attended. Parirenyatwa OI/ART clinic started to offer antiretroviral 
therapy the same year pilot sites were established in Zimbabwe. The first patient 
was initiated on antiretroviral drugs on the 6th of July 2004. To date more than  
13 000 patients have been registered at the clinic. The OI/ART Clinic caters for 
people mainly from the city of Harare suburbs and surrounding areas which include 
Mazoe, Chishawasha and Arcturus. The clinic does not offer HIV Counseling and 
Testing services. Patients are referred from other testing sites which include New 
Start Centre and City of Harare council clinics.  
 
Assessment for antiretroviral therapy at Parirenyatwa OI/ART clinic is usually done 
over 3 visits which are usually spread over 2 weeks. The visits include Basic 
Counseling 1, Basic Counseling 2, Blood Collection for CD4 counting, ART 
Counseling 1, ART Counseling 2 and ART initiation.  Basic Counseling focuses on 
the basic issues about HIV & AIDS which include transmission, progression, benefits 
of ART, prevention, disclosure and positive living. Basic 1 is done in a group session 
while Basic 2 is done one on one in a single session with the counselor to recap 
issues discussed during Basic 1.  
  
After Basic Counseling patients are then booked to come for blood collection for CD4 
count testing. The CD4 result often takes a week for the results to be available. 
Patients with CD4 counts less than 350cells/mm3 are booked for ART counseling. 
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ARV 1 is done in a group session while ART 2 is done one on one and a single 
session with the counselor to recap issues discussed during ART 1.  ART 
Counseling covers issues to do with taking of antiretroviral therapy. These include 
frequency of taking drugs, storage of drugs, adherence and side effects. After ART 
counseling patients are then booked for ART initiation by a clinician. 
 
During the ART initiation visit patients are assessed for opportunistic infections and 
staged according to the WHO Staging system. Those with opportunistic infections 
are treated accordingly and ART is started when they are stable. ART is started to 
patients with CD4 count less than 350 cells/mm3 or those in WHO Stage III and IV. 
The first line regimen is comprised of tenofovir or zidovudine or stavudine plus 
lamivudine with either nevirapine or efavirenz. Those who are not eligible for ART 
are asked to return to clinic every 3–6 months for monitoring. 
 
1.2 RESEARCH PROBLEM 
Delay in initiation of antiretroviral therapy is a problem in many health facilities in 
Zimbabwe and beyond. Patients take time to present to health facilities to seek 
treatment soon after being tested for HIV infection. This delay often leads to increase 
in HIV & AIDS associated mortality and morbidity.  A new prevention-treatment 
paradigm recently introduced by WHO and UNAIDS, is the Treatment 2.0 strategy 
(Hirnschall & Schwartländer, 2011). One of the key elements of this strategy is 
advancing point of care diagnostics and other simplified diagnostics and monitoring 
tools to reduce waiting times for diagnosis and initiation of ART. It recommends CD4 
count testing just after HIV testing and referral to an antiretroviral initiating site for 
registration, assessment and consideration for antiretroviral drugs initiation 
 
Despite patients being referred to access treatment early at the clinic, the majority of 
patients often delay to come to seek treatment. Most of the patients come with 
advanced HIV disease which often responds poorly to antiretroviral therapy. The 
researcher conducted this research to determine the factors associated with delay in 
seeking antiretroviral therapy among patients starting treatment at Parirenyatwa 
OI/ART clinic.  
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1.3 RESEARCH QUESTION 
What are the factors associated with delay in seeking treatment among patients 
starting antiretroviral therapy at Parirenyatwa Hospital OI/ART Clinic? 
 
1.4 PROJECT JUSTIFICATION 
The research identified the factors associated with delay in seeking antiretroviral 
therapy among patients attending Parirenyatwa OI/ART clinic. In the developing 
countries of which Zimbabwe is part of, patients often delay to seek antiretroviral 
therapy due to various reasons which leads to high morbidity and mortality.  The 
findings of the research will be very useful in providing meaningful conclusions that 
can be implemented to reduce morbidity and mortality as well as improving the 
efficiency in the process of initiating antiretroviral therapy at the clinic. The results will 
be shared with relevant stakeholders including the Ministry of Health and Child 
Welfare (MOHCW); HIV counseling and testing sites and other relevant partners so 
that the morbidity and mortality associated with delay in initiation of antiretroviral 
therapy is reduced in Zimbabwe.   
 
1.5 AIM AND OBJECTIVES 
 
1.5.1 Aim 
The aim of the study was to determine the factors associated with delay in seeking 
treatment among patients starting antiretroviral therapy at Parirenyatwa Hospital 
OI/ART Clinic in order to come up with measures that will increase seeking of 
antiretroviral therapy among eligible patients. 
 
1.5.2 Objectives 
The following were the objectives of the research: 
1) To establish the patient‟s knowledge on the benefits of antiretroviral therapy. 
2) To identify the current referral system for patients receiving antiretroviral 
therapy at the clinic. 
3) To determine the socio-cultural and economic factors that causes patient‟s to 
delay in seeking antiretroviral therapy. 
4) To determine factors related to the clinic associated with delay in seeking 
antiretroviral therapy from the patient‟s perspective. 
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5) To make suggestions that will enable early starting of antiretroviral therapy 
among patients. 
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CHAPTER 2 – LITERATURE REVIEW 
 
Sub-Saharan Africa remains the most affected region in the global AIDS epidemic; 
with an estimated 22.9 million people living with HIV (WHO Progress Report, 2011)]. 
The number has been gradually increasing since people are now accessing 
antiretroviral therapy and now living longer.  However the prevalence of HIV infection 
has been declining in about 22 countries Sub –Saharan Africa (WHO Progress 
Report, 2011). The stage of HIV disease in infected individuals before starting 
HAART plays a crucial role in the success of treatment. Individuals with advanced 
HIV disease at the time of HAART initiation tends to respond poorly to treatment and 
have a higher mortality rate compared to those who initiate earlier (Egger et al, 
2002).  Late presentation also poses a higher cumulative risk of HIV transmission to 
others, considering that earlier presentation and HIV-suppressing treatment might 
otherwise reduce viral load and risk of transmission.  A significant proportion (15%-
43%) of HIV infected individuals in the developed world; present at clinics for care 
with advanced or severe disease HIV disease i.e. either in WHO stage 3 or 4 or CD4 
lymphocyte count ≤ 200 cells/lug (Chadborn et al, 2005). Late presentation prevents 
people living with HIV/AIDS from obtaining the maximal benefit of being started on 
HAART early, treated for opportunistic infections and benefiting from health 
education and prophylactic interventions that are more effective when implemented 
earlier. 
 
The introduction of HAART has significantly reduced the mortality and morbidity of 
people living with HIV/AIDS globally and in low and middle income countries the 
number of people on antiretroviral has increased by 17 fold since 2003 (WHO 
Progress Report, 2011). However access to these lifesaving drugs is still a challenge 
in many developed countries mainly in Sub-Saharan Africa region (Kigoz et al, 
2009). HIV infection without antiretroviral therapy in the vast majority of infected 
individuals gradually progresses to destroy the immune system leading to high 
morbidity and mortality.  
 
In many HIV/ AIDS care programmes in Africa, patients are assessed clinically and 
prepared for treatment for HAART over a period which varies between 4 to 12 weeks 
(ART-LINC of IeDEA, 2008). They typically attend the clinic on three or more 
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occasions when information and counselling is provided on adherence and other 
aspects of ART. Due to various reasons which lead to delay in seeking antiretroviral 
therapy pre-treatment mortality of around 30 deaths per 100 person-years has been 
reported from a study done in South Africa (Lawn et al, 2005). There are several 
factors associated with delay to seek care and treatment which include patients‟ 
sociocultural, economic and health system related factors. 
 
Disclosure is an important public health goal for a number of different reasons. It 
motivates sexual partners to seek testing, changes behaviour and ultimately 
decreases transmission of HIV, increased opportunities for social support and 
improves access to necessary medical care including antiretroviral treatment 
(Abaynew et al, 2011).  Not disclosing to a partner may result in delayed 
presentation.  This could be explained that the desire to hide one‟s HIV-positive 
status from a spouse may inhibit HIV care-seeking. According to a World Health 
Organization article, “Gender Dimensions of HIV Status Disclosure to Sexual 
Partners” (WHO, 2004) partners or spouses who do not disclose their status their 
partners are more likely to present late.  
 
HIV Stigma is associated with delayed presentation to care. UNAIDS defines HIV-
related stigma and discrimination as: “…a „process of devaluation‟ of people either 
living with or associated with HIV and AIDS…Discrimination follows stigma and is the 
unfair and unjust treatment of an individual based on his or her real or perceived HIV 
status.” (UNAIDS, 2003).The stigma might come from the community or from 
healthcare workers. The HIV infected individual will not be comfortable to attend the 
clinic due to fear of stigma from either fellow community members or healthcare 
workers at the clinic. Studies done in Mozambique (Posse et al, 2009) and Zambia 
(Fox et al, 2010) have supported the idea that HIV & AIDS stigma is associated with 
delay in care.  
 
Patients with low economic status often take time to be started antiretroviral therapy. 
Though antiretroviral therapy is for free in developed countries there is usually a cost 
to patient. The costs include transportation fees, laboratory tests and drugs for 
treatment of opportunistic infections. In terms of economic status, women are 
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affected more than men and those in rural communities are affected more than those 
in urban areas. 
  
Poor service delivery at the health care facility has also been associated with delay 
in initiation of antiretroviral therapy. Health facility factors associated with poor 
service delivery include lack of health personnel, infrastructure, equipment and 
material used to provide care (Posse, Meheus et al, 2008). On top of that 
organisational factors also play a significant role. Organizational factors refer to the 
manner in which resources are coordinated and controlled in the process of 
providing treatment (Posse et al, 2008). Resources might be available but poor 
management might result in poor service delivery.  In most HIV & AIDS clinics before 
patients are put on antiretroviral therapy they undergo a series of preparatory 
counseling sessions. These are often spaced which often delay starting of 
antiretroviral therapy. Blood investigations which include CD4 count often takes long 
time before the results are out. The turnover time can be weeks to months.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
9 
 
CHAPTER 3 - METHODOLOGY 
 
3.1 STUDY DESIGN AND POPULATION 
The research design was a cross – sectional quantitative survey. The reference and 
source populations for the study were HIV infected people in Zimbabwe and HIV 
infected people eligible for antiretroviral therapy in Harare, Zimbabwe respectively.  
The target population was adults 18 years and above but less than or equal 65 years 
who were starting antiretroviral therapy at Parirenyatwa Hospital OI/ART Clinic.  
 
3.2 SAMPLING 
The survey was carried over a period of two months, mid-September and mid – 
November 2012. All patients who started antiretroviral therapy during this period who 
met the eligibility criteria were given consent forms to participate in the study.  A total 
of 220 patients were started on antiretroviral therapy during the period and 80 of 
them met the criteria and consented to participate in the study. The response rate 
was 95%. The 80 participants included both those who started antiretroviral therapy 
early (n = 31) and those who delayed treatment (n = 49).  Patients who started 
antiretroviral therapy early were also included for comparison purposes.  Delay in 
starting antiretroviral was defined as starting antiretroviral therapy more than 28 days 
after being tested for HIV infection and requiring treatment. Patients out of the age 
range (less than 18 years and above 65 years), with history antiretroviral therapy 
exposure who were being reinitiated on therapy and those who had regular CD4 
count monitoring prior to starting treatment were excluded from the study. 
 
3.3 DATA COLLECTION 
Data was collected using a questionnaire. The questionnaire contained demographic 
data, sociocultural, economic and health facility factors associated with delay 
seeking antiretroviral therapy among other things.  The questionnaire was 
administered by the researcher who was the medical doctor who initiated the 
participants on antiretroviral therapy. A pre - test of the questionnaire was carried out 
on the first 10 research participants and the data collection tool was adjusted 
accordingly.  
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3.4 DATA HANDLING AND ANALYSIS 
After collection the data was entered into a Microsoft Access Database which was 
designed specifically to capture data of the study. Frequencies, proportions and 
others measures were calculated form the database using queries. The proportion of 
patients that delayed to seek antiretroviral therapy together with the associated 
factors was also identified using queries. Qualitative data was handled thematically. 
 
3.5 PERMISSION AND ETHICAL CONSIDERATIONS 
The permission to carry out the study was sought from Parirenyatwa OI/ART Clinic 
Sister in Charge, Supervising Consultant of Parirenyatwa Hospital OIC/ART and the 
Clinical Director of Parirenyatwa Group of Hospitals. The study was ethically 
approved by the Joint Research Ethics Committee of Parirenyatwa Group of 
Hospitals and University of Zimbabwe College of Health Sciences and the Research 
Ethics Committee of Stellenbosch University. A signed consent form was obtained 
from every participant prior to entry into the study. The consent form was both in 
English and Shona. No names were written on the data collection tools. 
Confidentiality was assured and maintained.  
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CHAPTER 4 – DATA PRESENTATION AND ANALYSIS 
 
 
4.1 RESULTS 
1. Patients who delayed to be initiated on HAART 
The aim of the study was to identify the factors associated with delay in the initiation 
of antiretroviral therapy. Delay was defined as starting HAART more than 28 days (4 
weeks) after being tested for HIV. Figure 1, shows the three Scatter Plots with 
ranges of days 0 – 2500, 0 – 500 and 0 – 100  to clearly show the spread the 
number of days between date tested for HIV and date started on antiretroviral 
therapy.  
 
Figure 1: Days between Date of HIV Test and Date Started on Antiretroviral 
Therapy 
 
 
The minimum number of days was four and the maximum number was 2008. The 
average numbers of the days between HIV test and antiretroviral therapy for the 80 
participants was 159 days, the mode 35 and median 41. Out the 80 participants who 
were initiated on antiretroviral therapy during the time of study only 31 were initiated 
on therapy within four weeks after HIV test. A total of 49 patients delayed using four 
weeks as the cut off of point. This means 60% of the participants delayed in starting 
antiretroviral therapy.  
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Figure 2, is a cumulative frequency of the 80 patients on the number of patients that 
were started on antiretroviral after a specific period. 
 
Figure 2: Cumulative Frequency of Patients Started on HAART after a Specific 
Period 
 
 
Out the 80 patients only 13 were started on antiretroviral therapy within 2 weeks of 
being tested for HIV infection, 31 within 4 weeks, 50 within 8 weeks, 60 within 12 
weeks and 64 within 16 weeks. This leaves about 16 patients who were started on 
therapy more than 16 weeks after being tested for HIV infection. The researcher 
analyzed variables of the questionnaire linking them to delay starting antiretroviral 
therapy. 
 
2. Demographic Data 
During the two months period 80 participants were recruited. Out of the 80, 39 were 
males and 41 were females.  The average age was 36 years. The minimum age was 
18 and the maximum age was 65. The median age group was 37 and the mode was 
36.  Out the 49 patients who delayed to be started on HAART 28 were females and 
21 were males. The graph below shows sex and the proportion that delayed starting 
HAART. 53% of the male participant delayed to start as compared to 68% of female 
participants. 
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Figure 3: Participants that Delayed HAART with Sex 
 
 
 
Figure 4 shows the marital status of the participants. The graph shows that the 
majority of the participants were married and the separated were least. As a 
percentage, 83% of never married, 55% of married, 54% of divorced, 75% of 
separated and 80% of widowed delayed starting antiretroviral therapy. 
 
Figure 4: Marital Status and Delayed HAART 
 
 
 
The employment status of the participants: 29 were not employed, 27 were 
employed on full time basis, nine were employed on part time basis, 12 were self-
employed and three were students. The majority of the participants were not 
employed. In terms of starting HAART early only seven of the not employed, 12 of 
the full time employment, five of the part time employment, seven of self- employed 
and none of the students did. Only 32% of the not employed started HAART early as 
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compared to 44%in those employed full time. Figure 5 below summarizes the 
employment and starting of antiretroviral therapy. 
 
Figure 5: Employment Status versus Starting HAART Early or Delayed 
 
 
 
Three of the participants had never been to school and 11 attended up to primary 
education alone. A total of 66 participants had a level of education above secondary. 
All the three participants who have never been to school delayed starting HAART, 
seven for primary, 31 for secondary and eight for tertiary/college. Figure 6, shows 
those participants level of education and the proportion that delayed starting 
antiretroviral therapy. 
 
Figure 6: Level of Education and Delayed HAART 
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3. HIV Testing 
The study grouped HIV testing models into Voluntary Counseling Testing (VCT) and 
Provider Initiated Testing and Counseling (PITC). A total of 47 (59%) of the 
participants were tested via VCT and the remaining 33 (41%) via PITC. Out of the 49 
patients who delayed starting HAART 28 were tested via VCT and the remaining via 
PITC. Figure 7, below shows the places participants got their HIV test.  
 
Figure 7: Place of HIV Test 
 
The majority of the patients were tested at New Start Centre followed by hospitals 
and clinics. None of the participants were tested during mobile testing and only one 
each for workplace, campaign and other. 
 
A total of 41 of the participants had their CD4 count tests done at the testing site. Out 
the 49 who delayed to start antiretroviral therapy 22 had there CD4 done counts 
done at the testing site and 27 had their CD4 counts tests done somewhere.  After 
an HIV test 61 (76%) of the participants were referred for antiretroviral therapy. Out 
of the 49 participants who delayed HAART, 33 were referred for HAART and 16 
were not and Table 1 below illustrates this. 
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Table 1: Referral for HAART and Delayed HAART 
 
 
HAART Referral 
 
 
Participants 
 
Delayed 
HAART 
 
 
Delayed 
HAART (%) 
Referred for 
HAART 
61 33 54 
Not Referred for 
HAART 
19 16 84 
 
 
After HIV testing 44 of the participants were given referral letters to take to the 
antiretroviral initiating site, and 36 were not given. Out of the 49 who delayed HAART 
27 were not given letters and 22 were given. This means 50% of those given referral 
letters delayed HAART which is lower as compared to 75% among those not given 
referral letters. 
 
Figure 8: Referral Letter and HAART Initiation 
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4. Counseling Sessions 
The researcher analyzed the duration of counseling. Patients attend a total of four 
counseling sessions. For the 80 participants the average duration of counseling 
sessions was six days, the mode was three and the median was also three. The 
minimum was one day and maximum was 70 days. Figure 9 below shows a Scatter 
plot for the 80 participants on the duration of counseling sessions. 
 
Figure 9: Scatter Plot on Duration of Counseling Sessions for the 80 
participants 
 
A total of 13 participants had counseling sessions duration above average that is 6 
days. Out of the 13 who had counseling session duration above 6 days, eight of 
them delayed starting antiretroviral therapy.  
 
5.  Laboratory Investigations 
A total of 33 participants had CD4 count done at the testing site, 19 at HAART 
initiation site, six in private and 22 had their CD4 counts done at other places. Figure 
10 below shows where the CD4 samples were taken. 
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Figure 10: Place of CD4 Testing 
 
The average duration between date CD4 sample taken and result out was 3 days, 
the mode was 0 days and the median was also 0 days. 11 participants paid for the 
CD4 test and 69 had their CD4 count done for free at various institutions. Out of the 
11 participants who paid for their CD4 counts seven of them delayed starting 
HAART. Apart from CD4 count patients are often asked to have other extra tests. 
Out the 80 participants nine were asked to have extra tests on top of the CD4 count 
and of those nine, eight of them delayed to start antiretroviral therapy. 
 
Figure 11: Extra Test(s) and Initiation of HAART 
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6.  Antiretroviral Therapy Initiation 
At Parirenyatwa OI/ART Clinic before patients are started on antiretroviral therapy 
they are booked a date to come and see a medical officer for initiation of treatment. 
Of the 80 participants 53 of them were started antiretroviral therapy on the booked 
date and 27 were not. Out of the 27 who were not started treatment on the booked 
date 21 (78%) of them delayed starting therapy. Figure 12 below shows some of the 
reasons why the 27 participants were not started HAART on the booked date. 
 
Figure 12: Reasons for Not Being Started on HAART on the Booked Date 
 
 
 
7. Partner Notification and Testing 
A total of 55 of participants had regular sexual partners and 25 had no regular sexual 
partners.  49 of the 55 with regular partners were staying together and majority has 
been staying together for more than 12 months. Figure 13 below shows the 
proportions of those with regular sexual partners and those without who started 
HAART early or delayed. The proportion of those without sexual partners who 
delayed HAART is larger (72%) as compared to those with regular sexual partners 
(56%). 
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Figure 13: Sexual Partner and HAART Initiation 
 
A total of 52 of the participants disclosed their status to their partners and 40 
partners of participants had disclosed their status. The reasons which participants 
mentioned for not disclosing included fear of rejection, marital conflict and absence 
of the other partner. Those who had their partners disclosed 10 of them were 
negative and 30 were positive. Of the 30 partners who were positive 13 of them were 
on antiretroviral therapy. Table 2 below shows partner antiretroviral therapy status 
and HAART initiation. 
 
Table 2: Partner Antiretroviral Therapy Status and Initiation of HAART 
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8. Stigma and Discrimination 
A total of 16 participants experienced stigma and discrimination. The forms of stigma 
and discrimination the participants‟ experienced included rejection, loss of 
employment, affected relationships, fear to meet familiar faces at the clinic plus 
testing site, being looked down upon, viewing HIV as a death sentence and fear 
among other things.  
Of the 16 patients who experienced stigma and discrimination 13 of them delayed 
starting antiretroviral therapy. Figure 14 below illustrates this. The percentage of 
those who experienced stigma and discrimination that delayed HAART (81%) is 
much higher as compared to those who did not experience stigma and discrimination 
(56%) 
 
Figure 14: Stigma & Discrimination and HAART Initiation. 
 
 
9. Distance and Transport to the Clinic 
The majority of the participants stay in the high density suburbs, followed by low 
density, medium density and finally those outside Harare.  Figure 15 shows the 
residential area and the proportion that delayed HAART. As a percentage the 
proportion that delayed HAART per each group high density (58%), medium density 
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the highest proportion of patients who delayed to be initiated on HAART. 
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Figure 15: Residential Area and Delayed HAART Initiation. 
 
 
 
The commonest mode of transport used by participants when coming to clinic is by 
public transport followed by private transport, walking and bicycle. Only one of the 
participants came to the clinic by bicycle and delayed to seeking antiretroviral 
therapy. Figure 16 below shows the proportion that delayed HAART in each group. 
 
Figure 16: Mode of Transport and HAART Initiation. 
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When asked whether the participant has failed to the clinic due to lack of transport or 
transport money 11 participants answered yes. Of those who failed to come because 
transport or money transport money eight of them delayed to seek antiretroviral 
therapy. 
 
10. Quality of Service at Parirenyatwa OI/ART Clinic 
The participants were asked to rank the quality of service they received they 
received at the clinic. Figure 17 below shows the results. 
 
Figure 17: Quality of Service at Parirenyatwa OI/ART Clinic According to 
Participants 
 
The majority of the participants (34%) ranked the service as excellent while only 1% 
ranked the services as very poor. A total of 11 participants ranked the services as 
average and below while the rest was above average. Out of the 11 who ranked the 
services average and below, six of them delayed to be started on antiretroviral 
therapy. 
 
When asked on the areas which needs improvement at the clinic the majority of the 
participants were worried with the time they time spent at the clinic. They said they 
spent a lot time sitting in queues before being attended in the reception, consultation 
rooms or at the pharmacy. They also raised the issue of confusion in at the clinic. 
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They said patients are not given directions properly to where they are supposed to 
go which leads to some of them being lost and confusion within the clinic corridors. 
Other issues raised included the poor communication skills of health workers; need 
to attend to serious patients first; creating a separate room for patient starting 
antiretroviral therapy; awareness of the clinic in the media and to increase the 
number of doctors among other things.  
 
4.2 DISCUSSION 
The study revealed that 61.3% of patients delayed seeking antiretroviral therapy 
using 4 weeks as the cut of point. This finding is consistent with the findings from the 
ART in Lower Income Countries collaboration of the International Databases to 
Evaluate AIDS (ART-LINC of IeDEA, 2008) in which they carried out a survey to 
evaluate antiretroviral therapy in resource limited setting. In the evaluation they 
found out that in Africa patients are assessed clinically and prepared for treatment 
for HAART over a period which varies between 4 to 12 weeks. In this study using the 
cumulative frequency 75% (n= 60) of the patients were started on antiretroviral 
therapy within 12 weeks leaving the other 25% not yet on antiretroviral therapy. This 
is however a worrying figure considering the current improvements in antiretroviral 
therapy programmes in developing world.  
 
Among the participants there were more females than males. The findings is 
however consistent with other studies. While traditional gender roles give men the 
power to deny women access to health care (Go et al. 2003), the physical and 
emotional strength associated with masculinity and power can also make it 
unacceptable for men to seek health care (Greig & Lang 2000). Women tends to 
have a better health seeking behaviour than men and also, women are often more 
likely than men to be tested for HIV because of them attending antenatal and child 
health clinics. Among those who delayed to seek antiretroviral therapy there were 
more women than men again and this can be attributed to the women‟s inferior 
economic position (Go et al. 2003). Marital status was also a factor in deciding 
whether some seek treatment early.  The study found that those with partners tend 
to seek treatment earlier than the divorced, widowed, never married or separated. 
The same applied to those with regular sexual partners than those without. This 
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might be due to the social support to those with partners. Partners tend to encourage 
each other to go for HIV testing and start treatment. 
 
Those who are not employed and without a source of income i.e. students, delayed 
to seek antiretroviral therapy. Though antiretroviral therapy is offered for free at 
Parirenyatwa OI/ART clinic there is often some cost associated with the process - 
the major cost being transport and treatment of opportunistic infections. Others 
studies have also found that lack of money to cover costs often delays treatment 
(Coetzee et al. 2004; Ehiri et al. 2005). Other low socio economic status which 
include low level of education, walking to the clinic, staying in areas of low status and 
staying outside Harare where associated with high proportions of participants who 
delayed to seek antiretroviral therapy. The study also showed that paying for the 
CD4 count and extra laboratory tests delays starting of treatment. This is due to the 
cost associated which most of the patients cannot afford due to poor socioeconomic 
status.  
The majority of the participants i.e. 59% were tested for HIV via voluntary counseling 
and testing (VCT). This can be explained by the fact that in Zimbabwe VCT was 
introduced very early and it is the model most people are used to through the New 
Start Centres which are the testing sites. Provided Initiated Testing and Counseling 
(PITC) was however introduced a few years back and more campaigns are needed 
to promote it. The popularity of the VCT is however confirmed by the finding that the 
majority of the participants were tested at New Start Centres. It however disturbing 
that among the participants none were tested via mobile testing and only one each 
was tested via campaigns and workplace initiatives. The findings show that the HIV 
testing strategy in Zimbabwe is still very weak. The focus is mainly at health 
institutions and the donor funded New Start Centres. There is minimal mobile and 
workplace HIV testing.  
The study also found out that after testing patients who were not referred to centres 
that starts HAART and those not given referral letters delayed to seek treatment as 
compared to those who were referred and given referral letters. The finding supports 
the importance of quality post-test counseling accompanied by referring patients to 
centres that offers treatment.  
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The study found that 52 (65%) participants had disclosed their HIV status to their 
partners. Out of the 52 who disclosed 56 % (n =29) which is the majority, delayed to 
seek antiretroviral therapy and 44 % (n=23) started antiretroviral therapy early. 
These findings are however contrary to other studies. According to the other studies 
(Carter, 2008 & Bartlett, 2009) HIV positive individuals who do not disclose their HIV 
status to their spouses/partners are more likely to present late to HIV & AIDS care 
compared with those who disclosed their HIV status the explanation being that the 
desire to hide one‟s HIV-positive status from a spouse may inhibit HIV care-seeking 
(Abaynew et al, 2011). 
 
The results of the study also showed that health system level barriers can also delay 
eligible patients from starting antiretroviral therapy. The average time a patient spent 
between registration and starting antiretroviral therapy for the 80 participants was 21 
days which is very high. From the qualitative data from the patients most of them 
complained of the long waiting times, shortage of health care workers and unfriendly 
attitude of some of the health care workers. These findings are consistent with 
finding from other studies (Coetzee et al. 2004; Ehiri et al. 2005 & Pose et al, 2008).  
 
The study showed that 38% (n =27) were not started on antiretroviral therapy on the 
date they were booked. Of those who were not started on therapy on booked date 
78% (n =21) delayed to started on therapy. The proportion is however very high. The 
majority of the patients were not started antiretroviral therapy on the booked date 
were not on Cotrimoxazole prophylaxis. According to clinical practice a patient 
cannot be started on antiretroviral therapy at the same time with Cotrimoxazole due 
to similarity of side effects. The finding shows that the routine of initiating patients on 
Cotrimoxazole prophylaxis is still poor at the clinic.  Treatment of opportunistic 
infections was next to Cotrimoxazole prophylaxis as a reason why patients were not 
started treatment on booked date. Treatment of opportunistic infections usually 
delays treatment due to the screening process, cost associated and fear of immune 
reconstitution inflammatory syndrome (IRIS) by the clinicians. 
 
The results of the study showed that HIV positive individuals who experienced HIV 
stigma and discrimination were significantly associated with seeking antiretroviral 
therapy late. Similarly studies done in India (Chakrapani et al, 2009) Mozambique 
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(Pose et al, 2009) and Zambia (Fox et al, 2010), reported the same results. This 
could be explained that AIDS stigma affects preventive behaviours such as HIV test-
seeking behaviour and care-seeking behaviour upon diagnosis even as access to 
care has become more common (Abaynew et al, 2011). 
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CHAPTER 5 
5.1 CONCLUSION  
The majority of participants delayed seeking antiretroviral therapy and the factors 
which were associated with delay in seeking antiretroviral therapy included female 
gender; lack of a partner; low level of education; low socio-economic status; 
treatment of opportunistic infections; extra laboratory tests on top of the CD4 count 
tests; not being on Cotrimoxazole Prophylaxis; not being referred for antiretroviral 
therapy by the testing site; stigma and discrimination. However disclosure was not 
associated with early seeking of antiretroviral therapy. Health system factors such as 
attitude of health care workers, shortage of staff and long waiting times were also 
identified as bottlenecks to patients seeking antiretroviral therapy early. 
Efforts to increase early starting of antiretroviral therapy should focus on addressing 
the referral system from testing sites to antiretroviral therapy initiating sites, 
improving efficiency of antiretroviral initiating sites, increasing point of care HIV & 
AIDS diagnostics tools and addressing patient‟s concerns such as stigma & 
discrimination. 
 
The study however had some limitations that could have influenced the findings. The 
study relied on participants‟ self-report of historical events which could lead to recall 
biases. The sample size was not large enough due to the time limit.  The analyses of 
seeking treatment late would not represent the characteristics of HIV positives who 
never attended the clinic (selection bias). Social desirability should also have 
affected responses given by participants due to the nature the questions (social 
desirability bias).  Moreover, the fact that the researcher who happens to be a 
clinician at the clinic was involved in data collection might have introduced an 
interviewer bias though measures were taken to avoid this. Finally the instrument 
used in this study is not generic which was not validated for use in Zimbabwe. 
 
5.2 RECOMMENDATIONS 
After attending testing sites, patients should be referred to centres which initiate 
antiretroviral therapy. The benefits of antiretroviral therapy should be discussed 
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during post- test counseling so that patients quickly consider starting treatment. The 
referral should be accompanied by a detailed referral letter. In the long term all 
testing centres should be in a position to offer CD4 count testing for quick 
assessment of immune status and later be in a position to start antiretroviral therapy 
so that all services are offered under one roof.  
For the Ministry of Health, the strategy for HIV testing should be widened. Among the 
participants very few were tested via mobile services, at the workplace or during a 
campaign. The Ministry should promote, finance and support HIV & AIDS at the 
workplace, testing campaigns and mobile HIV testing. 
For the Parirenyatwa OI/ART clinic, the average time (21 days) a patient spends 
between registration and initiation of antiretroviral therapy is high. Measures should 
be put in place so that the time becomes shorter. Activities such as counseling 
sessions and collection of bloods should be booked on the same days rather than on 
separate days to minimise the visits to the clinic.  
The clinic should also have proper signage and patients should be directed 
adequately to avoid confusion at the clinic. The issue of poor communication skills 
and attitude of some of the health care workers should be addressed maybe through 
training in public relations.  
The routine of initiating patients on Cotrimoxazole Prophylaxis should also be 
stressed at the clinic since quite a number of patients had their initiation of 
antiretroviral therapy deferred because of the fact that they were not on 
Cotrimoxazole due to the clinician‟s fear of the similarity of side effects with those of 
antiretroviral drugs.  
And finally to future researchers, more research into how implementation of point of 
care diagnostics in Zimbabwean setting can improve access to antiretroviral therapy 
is very necessary.   
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APPENDICES  
Appendix 1 - Questionnaire 
Demographic Data 
1. Patient OI Clinic Number ----------------------------    Registration Date (DD/MM/YYYY) ----/----/-------- 
2. Gender       ⃝  Male    ⃝  Female      Date of Birth (DD/MM/YYYY) ----/----/--------   Age 
3. Marital Status ⃝ Never Married ⃝ Married ⃝ Divorced ⃝ Separated ⃝ Widowed 
4. Employment Status ⃝  Not Employed ⃝  Full time Employment ⃝  Part time Employment                    ⃝  
Self Employed ⃝ Student 
5. Level of Education ⃝ Never been to school   ⃝  Primary    ⃝  Secondary       ⃝ Tertiary/College 
HIV Test Details 
6. Date of HIV Test (DD/MM/YYYY) ----/----/------ 
7. HIV Testing and Counseling Model ⃝  VCT  ⃝ PITC 
8. Reason for HIV Test      
⃝ Diagnosis     ⃝ Tuberculosis     ⃝ PMTCT      ⃝ STI       ⃝ Death of Spouse/Child    ⃝ Occupational  
⃝ Sexual Abuse ⃝ Family Member on ART       ⃝ Other   
9. Place of HIV Test     ⃝  New Start Centre     ⃝  Clinic   ⃝ Hospital   ⃝  Mobile ⃝  Workplace ⃝ Campaign ⃝  
Other (Please Specify) ------------                     
10. Was CD4 Count done by testing site?         ⃝  Yes          ⃝  No        
11. Where you referred to an antiretroviral initiating site by the testing site?  ⃝  Yes        ⃝  No 
12. If Yes where you given a referral letter ⃝  Yes     ⃝  No 
Counseling Sessions 
13. Date Booked for Basic Counselling Sessions (DD/MM/YYYY) ----/----/-------- 
14. Date of Completion of Basic Counseling (DD/MM/YYYY) ----/----/-------- 
15. Date Booked for Antiretroviral Therapy Counseling (DD/MM/YYYY) ----/----/-------- 
16. Date of Completion of Antiretroviral Therapy Counseling (DD/MM/YYYY) ----/----/-------- 
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Laboratory Investigations 
17. Place CD4 was taken ⃝ Testing Site  ⃝  ART Initiation Site ⃝  Private ⃝  Other (Please Specify) ---- 
18. Date CD4 sample Taken (DD/MM/YYYY) ----/----/--------  
19. Date CD4 Result was Out (DD/MM/YYYY) ----/----/-------- 
20. Did you pay for the CD4 Count? ⃝ Yes   ⃝ No 
21. Apart from the CD4 count were you requested to have other extra test(s) 
⃝  Yes    ⃝ No 
 22. Did you manage to have the test (s) done and bring back the result in time back to the hospital?      
⃝  Yes   ⃝  No 
23. If failed you to have the test (s) done and bring the result(s) back in time to the hospital state the 
reason(s) 
Reason(s)-------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------------------------------------- 
24. Was your initiation on antiretroviral drugs deferred because of laboratory test(s)?                           
⃝  Yes    ⃝  No  
Antiretroviral Therapy Initiation  
25. Where you started on antiretroviral drugs on the day you were booked? ⃝  Yes ⃝  No  
26. Date booked for antiretroviral therapy initiation (DD/MM/YYYY) ----/----/-------- 
27. Date started on antiretroviral therapy (DD/MM/YYYY) ----/----/-------- 
28. If you were not started on antiretroviral drugs on the booked date state the reason(s) 
⃝  Laboratory Test(s)  
⃝  Treatment of Opportunistic Infection(s) 
⃝  Counseling Sessions not completed 
⃝  Missed Appointment 
⃝  Other (Specify) ---------------------------------------------------------------------------------------------------------- 
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Quality of Services at Parirenyatwa OI/ART Clinic 
29. How do you rank the quality of service you service you received at Parirenyatwa OI/ART Clinic 
during your antiretroviral therapy initiation process? 
    ⃝ Very Poor  ⃝ Poor  ⃝ Average  ⃝ Good   ⃝ Satisfactory   ⃝ Very Good    ⃝ Excellent 
30. Which areas need improvement so that patients are started on antiretroviral therapy in time? 
--------------------------------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------------------------------------- 
Partner Notification and Testing 
31. Do you have a regular sexual partner? ⃝  Yes   ⃝  No         Do you stay together?  ⃝  Yes   ⃝  No  
32. If staying together, for how long? 
⃝  Less than 3 months 
⃝  Greater than or equal to 3 months but less than 6 months 
⃝  Greater than or equal to 6 months but less than 12 months 
⃝  Greater than or equal to 12 months  
35. Have you disclosed your status to your partner?   ⃝  Yes ⃝  No 
36. If you have not disclosed what are the reasons for not disclosing? 
--------------------------------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------------------------------------  
37. Has your partner disclosed his/her status to you? ⃝  Yes   ⃝  No  
38. If he/she has disclosed to you what is his/her HIV Status ⃝  Negative     ⃝  Positive 
39. If partner is Positive is he/she on antiretroviral therapy? ⃝  Yes    ⃝  No 
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Stigma & Discrimination 
40. Has HIV & AIDS stigma and discrimination deterred you from seeking antiretroviral therapy?  
⃝  Yes ⃝  No.   
If yes describe how? 
……………………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………………… 
Distance and Transport to Clinic 
41. Where do you stay?  
⃝ High Density Harare   ⃝ Medium Density Harare ⃝  Low Density Harare ⃝  Outside Harare 
42. What mode of transport do you use to come to the clinic? 
⃝  Walk     ⃝  Public    ⃝  Private   ⃝  Bicycle    ⃝  Other………………………………………………….. 
43. Have you ever failed to come to the clinic due to lack of transport or transport money? 
⃝  Yes  ⃝  No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
37 
 
Appendix 2 – Consent English 
 
STELLENBOSCH UNIVERSITY 
CONSENT TO PARTICIPATE IN RESEARCH 
 
  
FACTORS ASSOCIATED WITH DELAY IN STARTING ANTIRETROVIRAL 
THERAPY FROM THE PATIENTS’ PESPECTIVE: CROSS – SECTIONAL STUDY 
AT PARIRENYATWA OI/ART CLINIC 
 
You are asked to participate in a research study conducted by Dr Richard 
Makurumidze (MBchB – UZ, Dip in HIV Man- CMSA) from the Africa Centre of 
HIV/AIDS Management at Stellenbosch University in partial fulfillment of the 
requirements for MPhil in HIV/AIDS Management. The study will look into the factors 
associated with delay in starting antiretroviral therapy at Parirenyatwa Hospital 
OI/ART Clinic. You were selected as a possible participant in this study because you 
are among the patients starting antiretroviral therapy at the clinic. 
 
1. PURPOSE OF THE STUDY 
 
The aim of the study is identify factors associated with delay in starting antiretroviral 
therapy among eligible patients starting antiretroviral therapy at Parirenyatwa 
OI/ART clinic and to make recommendations on how to improve the process of 
accessing antiretroviral therapy at the clinic and in Zimbabwe. Many people in 
Zimbabwe who are HIV infected often takes time to come to seek antiretroviral 
therapy due to various reasons and this has led to increase in HIV associated 
illnesses and death. 
 
2. PROCEDURES 
 
If you volunteer to participate in this study, you will be asked questions by the 
researcher. The process will last between 10 and 15 minutes. The questionnaire will 
be completed once at Parirenyatwa OI/ART clinic. 
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3. POTENTIAL RISKS AND DISCOMFORTS 
 
You might feel uncomfortable in discussing your HIV & AIDS issues and experiences 
in which case the wish to continue or stop participation will be respected. Refusal to 
participate in the study will not influence the service or treatment you will receive at 
the clinic. In case of a problem the researcher will refer you to specific services as 
needed. The services might include counseling and other necessary forms of 
support. 
 
4. POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY 
 
The study will identify factors associated with delay in seeking antiretroviral therapy 
among patients starting antiretroviral therapy at Parirenyatwa OI/ART clinic in order 
to inform evidence based interventions and policies to prevent delay in accessing 
antiretroviral therapy. Though you will not benefit directly, your participation in the 
study will contribute to the understanding of factors so that measures can be put in 
place for future patients.  
 
5. PAYMENT FOR PARTICIPATION 
 
You will not receive any payment for participating in this study.  
 
6. CONFIDENTIALITY 
 
Any information that is obtained in connection with this study and that can be 
identified with you will remain confidential and will be disclosed only with your 
permission or as required by law. Confidentiality will be maintained by use of a study 
number to identify participants. All the collected data will be kept securely and only 
the researcher will have access to it. The results of this study will be presented to 
Africa Centre for HIV/AIDS Management and may be presented or published in 
professional settings but the identities of all participants will remain anonymous.   
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7. PARTICIPATION AND WITHDRAWAL 
 
You can choose whether to be in this study or not.  If you volunteer to be in this 
study, you may withdraw at any time without consequences of any kind.  You may 
also refuse to answer any questions you don‟t want to answer and still remain in the 
study. The investigator may withdraw you from this research if circumstances arise 
which warrant doing so. Refusal to participate or being withdrawn from this study will 
not influence the service or treatment you will receive at the clinic 
 
8. IDENTIFICATION OF INVESTIGATORS 
 
If you have any questions or concerns about the research, please feel free to contact  
Dr Richard Makurumidze (Principal Investigator)                           
Parirenyatwa Hospital OI/ART Clinic,  
Harare.  
Zimbabwe 
Cellphone: - +263772759296.  
Email:-ricmanie2000@yahoo.com  
 
Greg Munro (Supervisor) 
University of Stellenbosch 
Africa Centre for HIV & AIDS Management 
Stellenbosch, South Africa 
Email:- greg@sybaweb.co.za 
 
9.   RIGHTS OF RESEARCH SUBJECTS 
 
You may withdraw your consent at any time and discontinue participation without 
penalty.  You are not waiving any legal claims, rights or remedies because of your 
participation in this research study.  If you have questions regarding your rights as a 
research subject, contact Ms Maléne Fouché [mfouche@sun.ac.za; 021 808 4622] 
at the University of Stellenbosch, Division for Research Development. 
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SIGNATURE OF RESEARCH SUBJECT OR LEGAL REPRESENTATIVE 
 
The information above was described to [me/the subject/the participant] by                     
[name of relevant person] in [English/Shona/other] and [I am/the subject is/the 
participant is] in command of this language or it was satisfactorily translated to 
[me/him/her]. [I/the participant/the subject] was given the opportunity to ask 
questions and these questions were answered to [my/his/her] satisfaction.  
 
[I hereby consent voluntarily to participate in this study/I hereby consent that the 
subject/participant may participate in this study. ] I have been given a copy of this 
form. 
 
________________________________________ 
Name of Subject/Participant 
________________________________________ 
Name of Legal Representative (if applicable) 
________________________________________   ______________ 
Signature of Subject/Participant or Legal Representative  Date 
 
 
SIGNATURE OF INVESTIGATOR  
 
I declare that I explained the information given in this document to 
__________________ [name of the subject/participant] and/or [his/her] 
representative ____________________ [name of the representative]. [He/she] was 
encouraged and given ample time to ask me any questions. This conversation was 
conducted in [*English/*Shona/*Other] and [no translator was used/this conversation 
was translated into ___________ by _______________________]. 
 
________________________________________  ______________ 
Signature of Investigator     Date 
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Appendix 3 – Shona Consent 
 
STELLENBOSCH UNIVERSITY 
GWARO REKUNZWISISA NEKUBVUMA KUPINDA MUCHIDZIDZO 
 
TSVAKURUDZO YEZVIKONZERO ZVINOITA KUTI VARWERE VANONOKE 
KUTANGA MAPIRITSI EKURAPA CHIRWERE CHESHURAMATONGO 
PACHIPATARA CHE PARIRENYATWA. 
 
Zita Remudzidzi  : Dr Richard Makurumidze  
Dhipatimendi  : OI/ART Clinic   
Chikoro   : Africa Centre of HIV/AIDS Management,    
Stellenbosch University  
 
MAVAMBO 
Murikukumbirwa kuti mupinde muchidzidzo chine zita rakanyorwa pamusoro. Ichi 
chidzidzo chiri kuitwa kuti mudzidzi awane magwaro edzidzo epamusoro. Chidzidzo 
ichi chinenge chichitsvakurudza zvikonzero zvinota kuti varwere vanonoke kutanga 
mapiritsi ekurapa chirwere cheshuramatongo paParirenyatwa OI/ART Clinic. 
Makaonekwa makakodzera semumwe anokwanisa kupinda muchirongwa ichi sezvo 
muri mumwe weavo varikuda kutanga mapiritsi.  
 
1. DONZO RECHIDZIDZO 
 
Donzo rechidzidzo nderekutsvakurudza zvikonzero zvinoita kuti varwere vanonoke 
kutanga mapiritsi uye nekushandisa ruzivo urwu  kugadzirisa nzira dzingashandiswe 
pakuvandudza chirongwa ichi pakiriniki apa pamwe nemuZimbabwe. Vanhu vazhinji 
vane utachiwana hwe HIV muZimbabwe vanonoka kunotsvaka rubatsiro rwekupinda 
pachirongwa chekumwa mapiritsi nekuda kwezvikonzero zvakasiyana-siyana izvi 
zvinoita kuti zvirwere nendufu zvinyanye kuwanda zvichikonzerwa neutachiwana 
hweHIV. 
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2. ZVICHAITWA KWAURI 
 
Uchinge wazvipira kupinda muchirongwa ichi, muchabvunzwa mibvunzo iri pabepa 
nemudzidzi. Izvi zvingatore maminitsi 10 kusvika ku 15. Mibvunzo iyi munoibvunzwa 
kamwe chete pakiriniki pano. 
 
3. NJODZI DZAMUCHASANGANA NADZO 
 
Munogona kusava makasununguka pakukurukura nezve utachiwana hwe HIV 
pamwe nezve AIDS asi sarudzo yekuenderera mberi nechirongwa ichi kana kurega 
inoremekedzwa zvikuru. Sarudzo yenyu yekusapinda muchidzidzo haizokanganise 
kurapwa kwamuichaitwa. Kana mukasangana nematambudziko, mudzidzi anovapo 
kukubatsirai nezvamunenge muchida. 
 
4. ZVAMUCHAWANA MUCHIDZIDZO ICHI 
 
Chidzidzo ichi chichatsvakurudza zvikonzero zvinota kuti varwere vanonoke kutanga 
mapiritsi ekurapa shuramatongo pakirinika yeParirenyatwa OI/ART kuitira kuti 
chirongwa ichi chivandudzwe.. Hapana mubhadharo wamuchawana kubva 
pachirongwa ichi, asi kuti kupinda muchidzidzo kwamuchaita kuchabatsira 
mukunzwisisa kuitira kuti veruzhinji vazobatsirikawo muneramangwana. 
 
5. MUBHADHARO  
 
Hamuzowani mubhadharo wekupinda muchirongwa ichi. 
 
6. KUCHENGETEDZWA KWEUMBOO HWENYU 
 
Zvese zvamuchataura nezvichabuda muchidzidzo chino zvichagara panzvimbo 
yakachengeteka uye zvinobuda chete kana imi muchinge matendera kana kuti 
zvatenderwa nemutemo. Mazita enyu achachengetedzwa kuburikidza nekushandisa 
nanhamba. Zvichabuda muchidzidzo chino zvichapihwa ve Africa Centre for 
HIV/AIDS Management uye zvinogona zvakare kutsikiswa mumagwaro ezveutano.  
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7. KUPINDA NEKUBUDA MUCHIRONGWA  
 
Unogona kusarudza kupinda kana kubuda muchirongwa.  Kana wabvuma kupinda 
muchirongwa ichi, unotenderwa kuzobuda machiri pasina kana matambudziko. 
Unotenderwa zvakare kusapindura mibvunzo yausingade ugorambazve uri 
muchidzidzo ichochi. Mudzidzi anogona kukuburitsa muchidzidzo ichochi kana 
achiona paine zvikonzero zvinokodzera kudaro. 
 
8. MAZITA EVATSVAKURUDZI 
 
Kana uine mibvunzo chero zvaungade kunzwisisa pamusoro pechidzidzo ichi, 
sununguka kubata vanotevera:- 
 
 Dr Richard Makurumidze ( Mudzidzi) 
Parirenyatwa Hospital OI/ART Clinic,  
Harare.  
Zimbabwe 
Cellphone: - +263772759296  
Email:-ricmanie2000@yahoo.com  
 
Greg Munro (Murairidzi) 
University of Stellenbosch 
Africa Centre for HIV & AIDS Management 
Stellenbosch, South Africa 
Email:- greg@sybaweb.co.za 
 
9.  KODZERO  YEPARTICIPANT 
 
Unotenderwa kubuda muchidzidzo ichi chero nguva pasina zvinoitika kwauri.  
Hautenderwi kushandisa mukana wechirongwa ichi sekodzero yekurapwa kana 
kuwana dzimwewo kudzero zvisina kutenderwa muchidzidzo chino. Kana uine 
mibvunzo ingaite nezvekodzero dzako pamusoro pechidzidzo ichi taura na Ms 
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Maléne Fouché [mfouche@sun.ac.za; 021 808 4622] veku University of 
Stellenbosch, Division for Research Development. 
 
Zita reParticipant…………………………………………………………………………… 
 
Saini ya Participant kana Saini yemumiririri weParticipant……………………………… 
 
Nguva ………………………………… Zuva……………………………………………… 
 
Ukama hwemumiriri ne Participant…………………………………………………….. 
 
Saini youmufakazi…………………………………Zuva………………………………… 
 
Saini yemudzidzi………………………Zuva…………………………………………….. 
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Appendix 4 – Stellenbosch REC Approval 
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Appendix 5 – JREC Approval 
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